GeneTether Therapeutics Inc.

Equities

GTTX

CA37187D1087

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 15:19:38 2024-06-24 EDT			5-day change	1st Jan Change
0.05 ^CAD	0.00%		+150.00%	+25.00%

05-30	GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-30	5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	CI

GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 29, 2024 at 06:30 pm

GeneTether Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.144222 million compared to USD 0.204338 million a year ago.

Latest news about GeneTether Therapeutics Inc.

GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	03-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-27	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	23-09-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	23-03-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022.	22-09-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-26	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
GeneTether Therapeutics Inc. has completed an IPO.	22-03-29	CI
GeneTether Therapeutics Inc. announced that it has received CAD 4.5 million in funding	22-03-28	CI
GeneTether Therapeutics Inc. announced a financing transaction	22-03-21	CI
GeneTether Therapeutics Inc. has filed an IPO.	21-11-04	CI
GeneTether Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	21-11-03	CI
GeneTether Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	21-11-03	CI

Chart GeneTether Therapeutics Inc.

Duration

Period

More charts

Company Profile

GeneTether Therapeutics Inc. is a Canada-based genetic medicines company focused on creating gene editing therapies based on its proprietary GeneTether platform. The Company's platform technology uses a proprietary method to tether donor deoxyribonucleic acid (DNA) templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. By positioning a donor DNA template directly at the site of a double strand break, the Company's GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template. It is building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. The Company's GeneTether platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENETETHER THERAPEUTICS INC.	+25.00%	1.42M
MODERNA, INC.	+38.36%	52.5B
LONZA GROUP AG	+36.73%	39.31B
IQVIA HOLDINGS INC.	-8.63%	39.01B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	28.2B
CELLTRION, INC.	-11.17%	26.57B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.2B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.62B
BIO-TECHNE CORPORATION	-5.30%	11.74B

Other Biotechnology & Medical Research